Skip to content

Study · Case report or series · n = 1 · 2025

2 results

Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report.

Lee ATM, Park CJ, Arter ZL, Nagasaka M, Ou SI

Lung Cancer (Auckland, N.Z.)25 Dec 2025

PMID41477303 (opens in a new tab)PMCIDPMC12747890 (opens in a new tab)DOI10.2147/lctt.s549011 (opens in a new tab)PepBankPUB-41477303
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a patient with alectinib-induced weight gain, semaglutide was followed by weight loss.

    In plain wordsIn one patient who gained weight on alectinib, weight loss followed semaglutide treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss in alectinib-induced weight gain
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here, we report a patient's case who had gained significant weight during still on-going 12-year treatment with alectinib and achieved weight loss through semaglutide but discontinued several months after starting semaglutide due to acute gallstone pancreatitis requiring emergency cholecystectomy.
  2. 02HumanCase report or seriesSafety outcome

    In a patient treated with semaglutide for alectinib-induced weight gain, acute gallstone pancreatitis needing emergency cholecystectomy led to discontinuation of semaglutide.

    In plain wordsOne patient stopped semaglutide because of acute gallstone pancreatitis that needed emergency gallbladder removal; the report cannot prove semaglutide caused it.

    Peptide
    Semaglutide
    Outcome
    Not applicableAcute gallstone pancreatitis
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here, we report a patient's case who had gained significant weight during still on-going 12-year treatment with alectinib and achieved weight loss through semaglutide but discontinued several months after starting semaglutide due to acute gallstone pancreatitis requiring emergency cholecystectomy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.